Guido Wuerth

As the radiopharmaceuticals field diversifies, we see more companies using a range of targeting molecules. There are distinct opportunities and challenges for using smaller targeting formats based on circulation time, tumor retention, stability and kidney retention. It’s important to consider these properties when designing optimal radiopharmaceutical drugs.

Join this interactive deep dive to:

• Explore challenges in integral membrane target identification and mining for peptides and mini proteins
• Assess modifications to avoid kidney toxicities
• Understand novel chelator innovations to explore how to alter pharmacokinetics and biodistribution
• Addressing biological half-life and blending with payload